Abstract
We recently reported artemisinin-resistant, uncomplicated Plasmodium falciparum malaria in Pursat, western Cambodia.1 Artemisinin resistance manifests as a slow parasite clearance rate (ie, a long parasite clearance half-life). A concern is that parasite clearance rates might be slower in patients with severe malaria2 who receive artemisinin monotherapy parenterally3 until they can take an artemisinin-based drug combination orally. To investigate this possibility, in 2010 we assessed parasite clearance in 30 patients with severe malaria in Pursat, with use of a protocol (ClinicalTrials.gov identifier: {type:clinical-trial,attrs:{text:NCT00341003,term_id:NCT00341003}}NCT00341003) approved by Cambodia’s National Ethics Committee for Health Research and the National Institute for Allergy and Infectious Diseases Institutional Review Board. Adults or parents of child participants gave written informed consent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
